Get the Stockscreener App
89.07
2.08%
-1.89
After Hours:
89.07
Arcellx Inc stock is traded at $89.07, with a volume of 320.04K.
It is down -2.08% in the last 24 hours and up +5.65% over the past month.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
See More
Previous Close:
$90.96
Open:
$91.44
24h Volume:
320.04K
Relative Volume:
0.61
Market Cap:
$4.88B
Revenue:
$144.75M
Net Income/Loss:
$-53.89M
P/E Ratio:
-22.49
EPS:
-3.96
Net Cash Flow:
$-42.88M
1W Performance:
+2.12%
1M Performance:
+5.65%
6M Performance:
+71.62%
1Y Performance:
+67.39%
1-Day Range:
$88.51
$92.92
1-Week Range:
$85.88
$95.50
52-Week Range:
$46.42
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
89.07 | 4.88B | 144.75M | -53.89M | -42.88M | -3.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
Arcellx, Inc. Reports Q3 2024 Earnings Highlights - TipRanks
Arcellx, Inc. (NASDAQ:ACLX) Stock Holdings Lowered by Thrivent Financial for Lutherans - MarketBeat
Principal Financial Group Inc. Decreases Stake in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Eagle Asset Management Inc. Lowers Stock Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Arcellx Inc - GuruFocus.com
(ACLX) Proactive Strategies - Stock Traders Daily
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice - MSN
arcellx CFO Michelle Gilson sells $156,508 in shares By Investing.com - Investing.com Canada
arcellx CFO Michelle Gilson sells $156,508 in shares - Investing.com India
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? - MSN
First Turn Management LLC Makes New Investment in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Position Reduced by Victory Capital Management Inc. - MarketBeat
First Week of January 2025 Options Trading For Arcellx (ACLX) - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Down 5.8% in October - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Arcellx (NASDAQ:ACLX) Shares Down 6.4%What's Next? - MarketBeat
Perceptive Advisors LLC Adjusts Position in Arcellx Inc - GuruFocus.com
Paradigm Biocapital Advisors LP Acquires Significant Stake in Ar - GuruFocus.com
arcellx director Kavita Patel sells $159,495 in stock - Investing.com
FMR LLC Adjusts Stake in Arcellx Inc - GuruFocus.com
arcellx CFO Michelle Gilson sells $1.24 million in stock By Investing.com - Investing.com South Africa
Arcellx director Kavita Patel sells $5.97 million in stock - Investing.com
arcellx CFO Michelle Gilson sells $1.24 million in stock - Investing.com
Arcellx director Kavita Patel sells $5.97 million in stock By Investing.com - Investing.com UK
Truist reaffirms Buy on Arcellx, cites long cash runway and positive CAR-T safety profile - Investing.com
US Bancorp DE Acquires 2,851 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - Defense World
Objective long/short (ACLX) Report - Stock Traders Daily
Piper Sandler Forecasts Strong Price Appreciation for Arcellx (NASDAQ:ACLX) Stock - Defense World
Arcellx Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
HC Wainwright Has Optimistic Outlook of Arcellx Q3 Earnings - Defense World
Analyst Expectations For Arcellx's Future - Benzinga
Arcellx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arcellx (NASDAQ:ACLX) Hits New 1-Year High on Analyst Upgrade - Defense World
Arcellx earnings missed by $0.14, revenue fell short of estimates - Investing.com UK
HC Wainwright Estimates Arcellx's Q3 Earnings (NASDAQ:ACLX) - MarketBeat
HC Wainwright Boosts Arcellx (NASDAQ:ACLX) Price Target to $95.00 - Defense World
Needham & Company LLC Reiterates Buy Rating for Arcellx (NASDAQ:ACLX) - Defense World
Morgan Stanley Forecasts Strong Price Appreciation for Arcellx (NASDAQ:ACLX) Stock - Defense World
Bank of America Raises Arcellx (NASDAQ:ACLX) Price Target to $100.00 - Defense World
Arcellx : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q) - Marketscreener.com
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights - BioSpace
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? - MSN
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arcellx stock soars to all-time high of $97.61 amid robust growth - Investing.com India
Arcellx (NASDAQ:ACLX) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Arcellx (ACLX) Releases Clinical Data from Phase 1 and iMMagine-1 Studies for Multiple Myeloma Patients On November 5, 2024, Arcellx, Inc. (NASDAQ: ACLX) made public an abstract containing fresh clinical data from its Phase 1 and iMMagine-1 - Defense World
Arcellx price target raised to $106 from $81 at Morgan Stanley - Yahoo Finance
How Arcellx (ACLX) Stock Stands Out in a Strong Industry - MSN
ASH ’24: Arcellx Mounts Strong Challenge To Myeloma CAR-T Rival Carvykti - News & Insights
Arcellx stock target increased, rating held on positive trial data - Investing.com
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):